New cancer combo enters safety testing for dozens of tumor types
NCT ID NCT03983954
Summary
This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast, lung, and esophageal cancers, who have few other treatment options. The main goal is to see how well patients tolerate the drugs and to identify any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
All India Institute of Medical Sciences
New Delhi, New Delhi, 110029, India
-
Basavatarakam Indo-American Cancer Hospital & Research Institute
Hyderabad, Telangana, 500034, India
-
National Cancer Institute
Jhajjar, Haryana, 124105124105, India
-
PMCH (Pacific Medical College & Hospital)
Udaipur, Rajasthan, 313001, India
-
Rabin Medical Center
Petah Tikva, Israel
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Shalby Hospital
Ahmedabad, Gujarat, 380015, India
-
Sheba Medical Center
Ramat Gan, 52621, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
Conditions
Explore the condition pages connected to this study.